James E. Flynn decreased its stake in Sangamo Therapeutics Inc (SGMO) by 40.33% based on its latest 2017Q3 regulatory filing with the SEC. Deerfield Management Company sold 441,305 shares as the company’s stock rose 95.00% with the market. The hedge fund run by James E. Flynn held 653,000 shares of the health care company at the end of 2017Q3, valued at $9.80 million, down from 1.09 million at the end of the previous reported quarter. Deerfield Management Company who had been investing in Sangamo Therapeutics Inc for a number of months, seems to be less bullish one the $1.39B market cap company. The stock decreased 3.81% or $0.65 during the last trading session, reaching $16.4. About 976,768 shares traded. Sangamo Therapeutics, Inc. (NASDAQ:SGMO) has risen 29.78% since December 31, 2016 and is uptrending. It has outperformed by 13.08% the S&P500.
Brad Dunkley increased its stake in Enerplus Corp (ERF) by 65.71% based on its latest 2017Q3 regulatory filing with the SEC. Waratah Capital Advisors Ltd bought 418,826 shares as the company’s stock declined 10.68% while stock markets rallied. The hedge fund run by Brad Dunkley held 1.06M shares of the oil & gas production company at the end of 2017Q3, valued at $10.42 million, up from 637,431 at the end of the previous reported quarter. Waratah Capital Advisors Ltd who had been investing in Enerplus Corp for a number of months, seems to be bullish on the $2.40 billion market cap company. The stock decreased 1.51% or $0.15 during the last trading session, reaching $9.79. About 961,826 shares traded or 4.25% up from the average. Enerplus Corporation (NYSE:ERF) has risen 69.92% since December 31, 2016 and is uptrending. It has outperformed by 53.22% the S&P500.
Among 6 analysts covering Enerplus Corp (NYSE:ERF), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Enerplus Corp had 14 analyst reports since July 21, 2015 according to SRatingsIntel. BMO Capital Markets upgraded the stock to “Outperform” rating in Friday, February 10 report. The rating was upgraded by UBS on Monday, November 9 to “Buy”. On Monday, June 6 the stock rating was upgraded by Macquarie Research to “Outperform”. As per Monday, November 9, the company rating was maintained by RBC Capital Markets. FirstEnergy Capital upgraded the stock to “Market Perform” rating in Monday, August 10 report. The stock of Enerplus Corporation (NYSE:ERF) earned “Buy” rating by Canaccord Genuity on Wednesday, August 17. The stock of Enerplus Corporation (NYSE:ERF) has “Outperform” rating given on Friday, December 18 by Raymond James. The rating was downgraded by Macquarie Research to “Neutral” on Friday, January 8. Raymond James reinitiated the stock with “Outperform” rating in Monday, June 6 report.
Waratah Capital Advisors Ltd, which manages about $788.22 million US Long portfolio, decreased its stake in Aramark (NYSE:ARMK) by 70,668 shares to 29,907 shares, valued at $1.22M in 2017Q3, according to the filing. It also reduced its holding in Costco Whsl Corp (NASDAQ:COST) by 77,928 shares in the quarter, leaving it with 24,994 shares, and cut its stake in Newfield Expl Co (NYSE:NFX).
Deerfield Management Company, which manages about $4.41 billion and $2.22 billion US Long portfolio, upped its stake in Arena Pharmaceuticals Inc by 655,600 shares to 1.07 million shares, valued at $27.34M in 2017Q3, according to the filing. It also increased its holding in Mckesson Corp (NYSE:MCK) by 413,583 shares in the quarter, for a total of 729,000 shares, and has risen its stake in Myokardia Inc.
Since August 11, 2017, it had 0 insider purchases, and 4 selling transactions for $1.02 million activity. 31,000 shares valued at $445,597 were sold by RINGO WILLIAM R on Wednesday, September 20.
Investors sentiment decreased to 1.57 in Q3 2017. Its down 0.02, from 1.59 in 2017Q2. It dropped, as 17 investors sold SGMO shares while 32 reduced holdings. 27 funds opened positions while 50 raised stakes. 51.93 million shares or 2.16% more from 50.83 million shares in 2017Q2 were reported. Iguana Mgmt Limited Liability accumulated 1.67% or 200,000 shares. Weiss Multi has invested 0.03% in Sangamo Therapeutics, Inc. (NASDAQ:SGMO). Drw Limited Liability Com holds 10,000 shares or 0.05% of its portfolio. Jacobs Levy Equity Mngmt invested in 31,340 shares. 213,027 were reported by Eam Investors Llc. Tiaa Cref Inv Limited Liability Company holds 0.01% of its portfolio in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) for 718,482 shares. Moreover, Frontier Capital Mngmt Company Limited Liability Corp has 0.05% invested in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) for 487,788 shares. Schwab Charles Inv Management stated it has 381,916 shares. Credit Suisse Ag holds 0.01% of its portfolio in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) for 423,855 shares. Baldwin Brothers Ma invested 0% in Sangamo Therapeutics, Inc. (NASDAQ:SGMO). Point72 Asia (Hong Kong) Limited has invested 0% in Sangamo Therapeutics, Inc. (NASDAQ:SGMO). Northern Trust has 1.07M shares. Peak6 Invests Limited Partnership holds 0% or 1,350 shares. The New York-based Prelude Capital Ltd Liability Com has invested 0% in Sangamo Therapeutics, Inc. (NASDAQ:SGMO). Pacad Investment holds 0.04% or 12,327 shares in its portfolio.
Analysts await Sangamo Therapeutics, Inc. (NASDAQ:SGMO) to report earnings on February, 27. They expect $-0.18 earnings per share, down 28.57% or $0.04 from last year’s $-0.14 per share. After $-0.15 actual earnings per share reported by Sangamo Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 20.00% negative EPS growth.
Among 10 analysts covering Sangamo Biosciences (NASDAQ:SGMO), 6 have Buy rating, 1 Sell and 3 Hold. Therefore 60% are positive. Sangamo Biosciences had 21 analyst reports since August 8, 2015 according to SRatingsIntel. The stock of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) earned “Overweight” rating by PiperJaffray on Wednesday, November 15. Jefferies reinitiated the stock with “Buy” rating in Thursday, June 22 report. The rating was maintained by Piper Jaffray on Thursday, August 10 with “Hold”. Jefferies reinitiated the stock with “Buy” rating in Friday, October 23 report. As per Tuesday, September 8, the company rating was downgraded by Zacks. The firm earned “Buy” rating on Friday, September 4 by Cowen & Co. The stock has “Neutral” rating by PiperJaffray on Wednesday, October 19. The firm earned “Hold” rating on Monday, August 14 by Wedbush. JP Morgan maintained Sangamo Therapeutics, Inc. (NASDAQ:SGMO) rating on Saturday, August 8. JP Morgan has “Overweight” rating and $22 target. On Wednesday, September 2 the stock rating was maintained by Wedbush with “Buy”.
The post As Enerplus (ERF) Share Value Declined, Shareholder Waratah Capital Advisors LTD Has Increased Its Holding; Deerfield Management Company Has Trimmed Sangamo Therapeutics (SGMO) Position as Valuation Rose appeared first on Stock Market News | HillCountryTimes | Get it Today.
from
https://www.hillcountrytimes.com/2017/12/31/as-enerplus-erf-share-value-declined-shareholder-waratah-capital-advisors-ltd-has-increased-its-holding-deerfield-management-company-has-trimmed-sangamo-therapeutics-sgmo-position-as-valuation-r/
No comments:
Post a Comment